135 completed, 24 terminated, 16 unknown, 5 active not recruiting. 87 Phase 2, 62 Phase 1, 26 Phase 3, 5 Not applicable, 2 Early Phase 1.
Follow this condition Literature Review of Leukemia, Myelomonocytic, Acute trials Research Report on Leukemia, Myelomonocytic, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 - Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2024-07-10 | 2025-01-01 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor - Acute Lymphoblastic Leukemia, Myeloblastic Leukemia | Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 56 | 2022-08-23 | 2023-09-28 |
| Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5) anti-ILT3 CAR-T - AML M4, AML M5 | Early Phase 1 | Unknown | Carbiogene Therapeutics Co. Ltd. | 25 | 2021-03-03 | 2021-03-23 |
| Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia umbilical cord blood - Leukemia, Myelomonocytic, Acute | Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 20 | 2021-02-01 | 2021-08-24 |
| CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS CPX-351 - Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia | Phase 2 | Active not recruiting | Case Comprehensive Cancer Center | 13 | 2021-01-14 | 2026-06-12 |
| A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Volasertib, Idarubicin, Cytarabine - Leukemia, Myeloid, Acute, Leukemia, Monocytic, Acute | Phase 1 | Withdrawn | University of Alberta | 2016-11-01 | 2017-04-05 | |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML metformin hydrochloride, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Northwestern University | 2 | 2015-03-11 | 2019-01-31 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia MEK inhibitor MEK162, idarubicin, cytarabine - Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | Bruno C. Medeiros | 1 | 2014-12-01 | 2017-12-06 |
| Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy eltrombopag olamine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 2 | Completed | Case Comprehensive Cancer Center | 31 | 2014-08-14 | 2026-08-07 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, omacetaxine mepesuccinate, decitabine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Terminated | Roswell Park Cancer Institute | 2 | 2014-07-01 | 2016-05-09 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Terminated | Steven E. Coutre | 4 | 2014-03-01 | 2019-04-05 |
| CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome liposomal cytarabine-daunorubicin CPX-351 - Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Completed | Rondeep Brar | 11 | 2014-02-03 | 2019-01-22 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia lenalidomide, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Stanford University | 17 | 2014-02-01 | 2018-10-29 |
| AML Therapy With Irradiated Allogeneic Cells fludarabine phosphate, cytarabine, donor lymphocytes - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Terminated | Rutgers, The State University of New Jersey | 6 | 2014-02-01 | 2021-08-24 |
| Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay antitumor drug screening assay, chemotherapy, biological therapy - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Completed | University of Washington | 16 | 2013-08-02 | 2018-07-11 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Erlotinib Hydrochloride, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 2 | Completed | M.D. Anderson Cancer Center | 29 | 2013-05-16 | 2020-01-07 |
| Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes pravastatin sodium, idarubicin, cytarabine - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Completed | Fred Hutchinson Cancer Center | 24 | 2013-05-01 | 2017-11-17 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia arsenic trioxide, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Withdrawn | Stanford University | 2013-05-01 | 2018-05-21 | |
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2013-05-01 | 2016-09-01 |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia tretinoin, lithium carbonate, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Completed | Paolo Caimi, MD | 12 | 2013-04-30 | 2017-04-27 |
Showing 20 of 187. Sign in to see all of them.
Leukemia, Myeloid, Acute (174) · Leukemia, Monocytic, Acute (166) · Leukemia, Erythroblastic, Acute (159) · Leukemia, Megakaryoblastic, Acute (156) · Congenital Abnormalities (123) · Leukemia (97) · Leukemia, Basophilic, Acute (53) · Leukemia, Eosinophilic, Acute (53) · Leukemia, Promyelocytic, Acute (37) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (37) · Myelodysplastic Syndromes (27) · Blast Crisis (23) · Leukemia, Myelomonocytic, Chronic (22) · Anemia, Refractory, with Excess of Blasts (20)
Hematologic Diseases (187) · Hemic and Lymphatic Diseases (187) · Leukemia, Myeloid (187) · Neoplasms by Histologic Type (187) · Neoplasms (186) · Bone Marrow Diseases (170) · Myeloproliferative Disorders (147) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (123) · Leukemia (90) · Disease Attributes (44) · Pathologic Processes (44) · Pathological Conditions, Signs and Symptoms (44) · Chronic Disease (43) · Immune System Diseases (38) · Immunoproliferative Disorders (38)
Cytarabine (82) · Etoposide (32) · Daunorubicin (31) · Filgrastim (26) · Idarubicin (26) · Mitoxantrone (22) · Busulfan (18) · Peripheral Blood Stem Cell Transplantation (17) · Cyclophosphamide (14) · Gemtuzumab (14) · fludarabine phosphate (14) · tipifarnib (11) · Azacitidine (10) · Clofarabine (10) · Gene Expression Profiling (9)
National Cancer Institute (NCI) (51) · SWOG Cancer Research Network (11) · Fred Hutchinson Cancer Center (10) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Roswell Park Cancer Institute (8) · Case Comprehensive Cancer Center (7) · Alliance for Clinical Trials in Oncology (6) · Eastern Cooperative Oncology Group (6) · Children's Oncology Group (5) · ECOG-ACRIN Cancer Research Group (4) · Memorial Sloan Kettering Cancer Center (4) · Northwestern University (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · M.D. Anderson Cancer Center (3) · Rutgers, The State University of New Jersey (3)
United States (142) · Canada (14) · France (11) · Italy (10) · Belgium (8) · Netherlands (8) · United Kingdom (8) · Germany (6) · Croatia (4) · Israel (4) · Austria (3) · Portugal (3) · Puerto Rico (3) · Switzerland (3) · Australia (2)
Judith Karp (6) · Sergio Amadori, MD (5) · Anjali Advani, MD (4) · B. Smith (4) · Roland Walter (4) · Alan K. Burnett, MD, FRCP (3) · Bruno de Medeiros (3) · Jerry Radich, MD (3) · Jorge Cortes (3) · Martin S. Tallman, MD (3) · Meir Wetzler, MD (3) · Thomas R. Chauncey, MD, PhD (3) · William Blum (3) · Anthony S. Stein, MD (2) · B. Douglas Smith, MD (2)
PMID 24383844, PMID 25527568, PMID 36184192, PMID 31171508, PMID 31375516, PMID 32499241, PMID 29926156, PMID 30523055, PMID 34162404, PMID 37267439, PMID 11331327, PMID 11585760, PMID 12750167, PMID 15339678, PMID 15514371, PMID 15761020, PMID 16275934, PMID 16484584, PMID 16670265, PMID 16932345, PMID 17315155, PMID 17339189, PMID 17562873, PMID 17640728, PMID 18571721, PMID 19010875, PMID 19092853, PMID 19109557, PMID 19289999, PMID 19291085, PMID 19710500, PMID 19794082, PMID 19804455, PMID 19826132, PMID 20038732, PMID 20460644, PMID 20522709, PMID 20716770, PMID 20952518, PMID 21239698, PMID 21393334, PMID 21551228, PMID 21791425, PMID 21791475, PMID 22001391, PMID 22133771, PMID 22627678, PMID 22733022, PMID 23256542, PMID 23443507
U01CA070095 (15), U10CA032102 (14), P30CA006973 (11), U10CA031946 (11), P30CA015704 (7), U10CA180821 (7), P30CA043703 (5), U10CA021115 (5), N01CM62204 (4), U01CA076576 (4), P30CA016056 (3), P30CA016672 (3), P30CA072720 (3), P30CA124435 (3), U01CA062491 (3)